Drug ID:Drug117
Drug Name:Vercirnon
CID:10343454
DrugBank ID:DB15250
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT01658605
Molecular Formula:C22H21ClN2O4S
Molecular Weight:444.9 g/mol
Isomeric SMILES:CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-]
Synonyms:Vercirnon; 698394-73-9; Traficet-EN; GSK-1605786; CCX282-B; Verecimon; GSK1605786; CCX-282-B; VERCIRNON [INN]; VERCIRNON [USAN]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt979 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) 20660125 Antagonist
dt980 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) 20582872 C-C chemokine receptor type 9 antagonist
dt981 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) None
dt982 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) Inhibitor
dt983 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) Modulator
dt984 10343454 Vercirnon 66 ACTBP6 Homo sapiens (human) Modulator
dt985 10343454 Vercirnon 10803 CCR9 Homo sapiens (human) 37713619 Modulator

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT00306215 A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease PHASE2 COMPLETED Amgen Crohn's Disease DRUG: CCX282-B Details
NCT00102921 Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease PHASE2 COMPLETED Amgen Crohn Disease DRUG: CCX282-B Details
NCT01827631 Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects PHASE1 COMPLETED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786 capsule Details
NCT01658605 A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis PHASE2 WITHDRAWN GlaxoSmithKline Colitis, Ulcerative DRUG: GSK1605786|OTHER: Placebo Details
NCT01611805 Japanese Phase I of GSK1605786 PHASE1 COMPLETED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786|DRUG: GSK1605786 Placebo Details
NCT01536418 An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease PHASE3 TERMINATED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786A|DRUG: GSK1605786A Details
NCT01489943 A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects PHASE1 COMPLETED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786 500 mg|DRUG: Midazolam 3 mg|DRUG… Details
NCT01318993 Open-Label Extension Study of GSK1605786A PHASE3 TERMINATED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786A Details
NCT01316939 GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease PHASE3 TERMINATED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786A|DRUG: Placebo|DRUG: GSK1605786A Details
NCT01277666 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease PHASE3 COMPLETED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786A|DRUG: GSK1605786A|DRUG: Placebo Details
NCT01114607 A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects PHASE1 COMPLETED GlaxoSmithKline Crohn's Disease DRUG: GSK1605786 ChemoCentryx: formulation A|DRUG… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as i…

PMID: 26400458
Year: 2015
Relationship Type: Treatment Score: 6.3

BACKGROUND: Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments. AIMS: To cond…

View Details